Swiss National Bank Has $172.06 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Swiss National Bank cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 306,000 shares of the biopharmaceutical company’s stock after selling 17,700 shares during the period. Swiss National Bank’s holdings in Regeneron Pharmaceuticals were worth $172,055,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Salomon & Ludwin LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $31,000. Caitlin John LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $34,000. Traub Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $38,000. Finally, Berbice Capital Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 300.0% during the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 60 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the transaction, the director directly owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This trade represents a 0.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 5,274 shares of company stock worth $4,142,738. Corporate insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of several research analyst reports. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. BMO Capital Markets upped their target price on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Canaccord Genuity Group raised their price target on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Finally, Royal Bank Of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $802.27.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $781.60 on Tuesday. The stock has a market cap of $82.63 billion, a PE ratio of 18.81, a P/E/G ratio of 2.04 and a beta of 0.40. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The stock’s 50 day simple moving average is $770.83 and its 200-day simple moving average is $690.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the company posted $12.07 earnings per share. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were paid a $0.94 dividend. The ex-dividend date was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.05%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.